Next Article in Journal
Antimicrobial Resistance in Livestock: A Serious Threat to Public Health
Previous Article in Journal
Stability Studies of the Dilution Series of Different Antibiotic Stock Solutions in Culture Medium Incubated at 37 °C
Previous Article in Special Issue
Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 6
10.3390/antibiotics13060550
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synergistic Combination of Aztreonam and Ceftazidime–Avibactam—A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania

by
Ioana Miriana Cismaru
1,
Maria Cristina Văcăroiu
1,*,
Elif Soium
1,
Tiberiu Holban
1,
Adelina Maria Radu
1,2,
Violeta Melinte
1,2 and
Valeriu Gheorghiță
1,2
1
Agrippa Ionescu Clinical Emergency Hospital, 011356 Bucharest, Romania
2
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(6), 550; https://doi.org/10.3390/antibiotics13060550
Submission received: 16 April 2024 / Revised: 3 June 2024 / Accepted: 4 June 2024 / Published: 12 June 2024
(This article belongs to the Special Issue Carbapenemases in Gram-Negative Bacteria: A Global Health Threat and Therapeutic Challenge)
Browse Figures
Review Reports Versions Notes

Abstract

:
With the increasing burden of carbapenem-resistant Klebsiella pneumoniae (CR-Kp), including high rates of healthcare-associated infections, treatment failure, and mortality, a good therapeutic strategy for attacking this multi-resistant pathogen is one of the main goals in current medical practice and necessitates the use of novel antibiotics or new drug combinations. Objectives: We reviewed the clinical and microbiological outcomes of seven patients treated at the “Agrippa Ionescu” Clinical Emergency Hospital between October 2023 and January 2024, aiming to demonstrate the synergistic activity of the ceftazidime–avibactam (C/A) plus aztreonam (ATM) combination against the co-producers of blaNDM + blaOXA-48-like CR-Kp. Material and Methods: Seven CR-Kp with blaNDM and blaOXA-48 as resistance mechanisms were tested. Seven patients treated with C/A + ATM were included. The synergistic activity of C/A + ATM was proven through double-disk diffusion in all seven isolates. Resistance mechanisms like KPC, VIM, OXA-48, NDM, IMP, and CTX-M were assessed through immunochromatography. Results: With a mean of nine days of treatment with the synergistic combination C/A + ATM, all patients achieved clinical recovery, and five achieved microbiological recovery. Conclusions: With the emerging co-occurrence of blaOXA-48 and blaNDM among Kp in Romania, the combination of C/A and ATM could be a promising therapeutic option.

1. Introduction

In recent years, some resistant and hypervirulent strains of Kp have obtained notable pathogenic properties, standing out as some of the most common microorganisms in serious and even fatal diseases [1].
According to a meta-analysis including 35 original studies addressing colonization with carbapenem-resistant Kp, which evaluated 37,661 patients from 18 countries between 2010 and 2021, the prevalence of colonization varies by location and ranges from 0.13 to 22%, with a pooled prevalence of 5.43% (3.73–7.42) [2].
Based on a report from the European Antimicrobial Resistance Surveillance Network between 2016 and 2020, the general burden of multidrug-resistant infections was estimated to be the highest in Greece, Italy, and Romania, with the highest individual yearly estimates occurring in Romania from 2018 to 2019 [3,4].
In parallel with the COVID-19 pandemic, despite all the prevention measures taken in Romania, another “silent pandemic” has been ongoing. The high use of antimicrobials in hospitalized patients has increased the rate of colonization with resistant microorganisms and favored the development of XDR bacteria, especially among oncologic patients and the seropositive population. Romania has jumped to the second position among EARS Net member states regarding carbapenem-resistant isolates [5,6,7,8].
According to Romanian national statistics for 2021, among 531 Kp strains, when 227 CR-Kp isolates were tested for colistin sensitivity, 36.7% were colistin-resistant. The increased circulation of pathogenic blaNDM Kp and the high percentage of colistin-resistant CR-Kp in the absence of therapeutic rescue regiments such as cefiderocol makes it imperative to devise clear strategies for prevention and treatment [9,10].
Starting in March 2022, data have shown an increasing incidence of blaNDM-1 and blaNDM-1/blaOXA-48-producing Kp in Germany and Denmark, coinciding with the outbreak of war in Ukraine. In 2021, Ukraine also reported high antimicrobial resistance in Gram-negative bacteria, including CR-Kp, in 64% of tested strains. In addition to increasing trends in travel and population mobility, the above epidemiological data must be taken into consideration regarding the carriage of multidrug-resistant organisms for the better implementation of prevention and control measures [11].
In times of constant epidemiological change, it is crucial to understand the pathogenic mechanism of Kp. Carbapenem hydrolysis is mainly mediated by enzymes classified as Ambler class A (KPC), class B (VIM, IMP, and NDM), and class D (OXA-48). The growing spread of NDM has created an urgent need to identify therapeutic options, as the effect of β-lactamases inhibitors has significantly decreased [12,13].
The EMA-approved antibiotic C/A has a bactericidal effect against Ambler classes A and C, and some of the D class isolates like blaOXA-48 CR-Kp, but it has no effect on Ambler class B isolates, so this combination does not affect metallo-β-lactamases (MBLs), including blaNDM [14,15]. When adding ATM to C/A, the inhibitory activity against carbapenem-resistant Enterobacteriaceae can be obtained owing to the stability of ATM against MBLs, as can the protection of avibactam against aztreonam-hydrolyzing enzymes like ESBLs and AmpC, expanding the effect of ATM + C/A on blaNDM and blaOXA-48 co-producers [16,17]. These enzymes are often associated with carbapenemases.
In the following case series study, we evaluated the clinical and microbiological outcomes of seven patients who received a combination of C/A plus ATM for co-producing blaNDM and blaOXA-48 Kp isolates.

2. Results

At our hospital, we experienced an increasing trend in CR-Kp infections, noting a growing number of XDR strains. Over 4 months, between October 2023 and January 2024, we identified 43 CR-Kp strains isolated from multiple sites.
In our case series, we selected seven patients admitted during this period with positive cultures for CR-Kp producing blaNDM, blaOXA-48, and CTX-M. Regarding their distribution among hospital wards, three of them were admitted to the ICU/surgical ward after surgical procedures, and four of them were admitted to medical wards.
All seven subjects were adult males aged between 57 and 84, with a mean of 66 years. No CR-Kp producing blaNDM and blaOXA-48 was isolated in any female patients. More than half of the subjects had prior contact with medical settings, as four out of the seven patients were hospitalized in the last 3 months, and four had undergone surgical procedures in the last 6 months. Regarding the risk factor of developing antimicrobial resistance, six out of the seven were treated with at least one course of antibiotics, and three were exposed to carbapenems in the last 3 months. The group characteristics show patients with multiple comorbidities, especially neurological, oncological, cardiac, and urological. The Charlson index score was between two and seven. Four patients tested positive for bacterial colonization with different MDR bacteria at a routine screening, including XDR Kp, VRE, MRSE, CPE, and ESBL. All the patients were exposed to invasive procedures, urinary catheterization was performed in all cases, and three patients had a CVC placed and were under orotracheal intubation during surgical procedures (Figure 1, Figure 2, Figure 3, Figure 4 and Figure 5).
None of the patients met the criteria for septic shock according to their SOFA scores; two were diagnosed with malignancies and underwent extensive abdominal surgery during hospitalization, but none received immunosuppressant therapy.
The specimens were collected from three different sites: four urinary, two intra-abdominal, and one blood culture. Only one subject had bacteriaemia, and the probable source was obstructive pyelonephritis, even though the urinary culture was negative. Two patients had symptomatic urinary infections, and two had asymptomatic urinary infections. Two intra-abdominal cultures were multi-bacterial, including CR-Kp, and were collected intraoperatively. In one case, control cultures could not be performed, as the patient did not undergo a second surgical procedure.
All the CR-Kp isolates were blaNDM, blaOXA-48, and CTX-M producers, and all had an MIC of >16 mg/L for meropenem and C/A and an MIC of >64 mg/L for ATM. Cefiderocol resistance was proven in one specimen and colistin resistance in six out of the seven. Fosfomycin resistance was proven in five out of the seven isolates (two were not tested). Furthermore, high resistance to tigecycline was noticed. The synergistic activity of C/A + ATM was demonstrated in all seven isolates (Table 1).
All patients received combination therapy with 2.5 g C/A every 8 h and 2 g of ATM every 8 h, infused over 3 h with no other associated antimicrobial agent. In one patient with end-stage kidney disease, higher 1.25 g doses of C/A q12h + 2 g of ATM q12h were administered at an eGFR of 20–30 mL/min, with intermittent dialysis sessions, to ensure higher serum concentration. We could not determine serum concentration measurements at our hospital. No other renal adjustments were necessary in the other cases. The treatment was generally well tolerated, with no major adverse reactions.
The treatment duration was between 7 and 14 days, with a mean of 9 days. All patients achieved clinical recovery, and five achieved microbiological recovery. In one case, control cultures could not be performed, and another patient had a positive culture at the end of treatment, but both subjects had good clinical and inflammatory responses. All urinary control cultures were negative on day 7 of treatment. The minimum hospital stay was 10 days, and two patients were hospitalized for more than 30 days owing to unrelated affections. On day 30, mortality was zero, and no re-admissions were registered on account of CR-Kp infections (Table 2).

3. Discussion

Modern medicine is threatened by growing antimicrobial resistance, especially among Gram-negative microorganisms, where resistance to β-lactams is most often mediated by β-lactamases. Throughout much of Europe, Northern Africa, and the Middle East, the OXA-48 enzyme has proliferated, becoming the most prevalent carbapenemase [18].
The first data regarding the presence of carbapenemase-producing Enterobacteriaceae (CPE) isolates in Romania were presented in a review by Cantón et al. in 2012, based on unpublished data [19]. In recent years, there has been an increase in reports of Kp isolates harboring two carbapenemases [20,21,22,23]. There is a growing number of strains that produce multiple carbapenemases in other enterobacterial species [24].
A total of 832 genome sequences of CR-Kp strains co-carrying two of the five major carbapenemase genes from 105 countries from 1980 to 2022 were retrieved from the NCBI GenBank database. The strains that co-carried blaNDM and blaOXA-48-like genes accounted for 665 out of the total (79.9%), ranking first, and strains that co-carried blaKPC and blaNDM genes accounted for 103 (12.4%), ranking second [25].
Despite our small amount of data from this small group of patients, our case series shows the importance of studying the mechanisms underlying the co-occurrence of multiple carbapenemase types and indicates a possible upward trend for CR-Kp co-producing blaOXA-48 and blaNDM in Romanian hospitals, calling for further research regarding the prevalence of highly resistant strains in our country.
In the current scenario, we aimed to highlight that having good knowledge of the epidemiological context and molecular mechanisms of CR-Kp can lead to appropriate therapeutic choices. It is crucial to understand which antibiotics are effective against each type of carbapenemase to tailor therapy and improve clinical outcomes. Our results showing CR-Kp strains co-carrying three mechanisms of antimicrobial resistance (blaNDM, blaOXA 48, and CTX-M) emphasize the need to improve the efficiency and accuracy of standard AMR data analysis and reporting workflows.
Starting in 2010, a few published Romanian studies have signaled the presence of blaOXA-48 and blaNDM Kp isolates in patients admitted to hospitals from different geographic areas. The first study was conducted between November 2013 and April 2014, and it described the local distribution of blaNDM-1, blaOXA-48, and blaOXA-181 in nine hospital isolates from central Romania, whereas the second one showed the distribution of CPE in two hospitals in Bucharest between 2011 and 2012 [26,27,28,29].
Between October 2023 and January 2024, we identified 43 CR-Kp strains, from which 7 strains were tested using immunochromatography, revealing blaNDM and blaOXA 48 enzyme co-production. All isolates demonstrated resistance to C/A, monobactams, and carbapenems, and one showed resistance to cefiderocol.
A six-month survey conducted between November 2013 and April 2014 at eight Romanian hospitals presented the first characterization of CR-Kp. It showed that among 75 non-susceptible isolates, 65 were carbapenemase producers. The most frequently identified genotype was blaOXA-48 (n = 51 isolates). Eight isolates were positive for the blaNDM-1 gene, four had the blaKPC-2 gene, and two were positive for blaVIM-1 [30].
Compared with previous studies, our findings strongly suggest that there is an underestimation of the prevalence of co-producing blaNDM and blaOXA-48 Kp isolates, and further research is a pressing priority, especially on the use of novel antibiotic combinations. The current guidelines recommend C/A plus ATM or cefiderocol alone for blaNDM-producing strains and C/A alone for blaOXA-48-producing strains for extra-urinary tract infections. There are no recommendations for when two or more resistance mechanisms are detected within the same Kp strain [31].
In our survey, all seven patients were treated with a combination of C/A and ATM. All achieved clinical recovery, and five achieved microbiological recovery with zero mortality and no re-admission owing to CR-Kp. We noticed no severe adverse events, although the safety of this combined drug therapy is not well established owing to a lack of data. However, the small number of patients enrolled and the short period of monitoring are limitations in this regard. Consistent with our promising outcomes, another published review highlighted the favorable outcomes of ten patients treated with C/A plus ATM in Spain, achieving clinical success in six of the subjects. All infections were caused by the hypervirulent strain KP-HUB-ST147, which is resistant to ATM and C/A [32].
Other data have demonstrated the success of the C/A and ATM combination in two different patients, the first with a hip arthroplasty site infection caused by an XDR NDM-1-producing strain of Enterobacter cloacae and the second with a suppurated thrombophlebitis and persistent bacteremia caused by an OXA-48/NDM-1-producing Kp, both pathogens with proven in vitro synergistic activity [33,34].
Our case series suggests that the C/A and ATM combination could be successfully used for patients with limited therapeutic solutions due to antimicrobial resistance or in countries with limited accessibility to cefiderocol. It is the only β-lactam active against MBL-producing Kp, but strains with reduced susceptibility to this compound are already emerging despite their short-term use [35].
Using our unpublished data, we identified a significant percentage of cases with resistance to cefiderocol, proven using the disk diffusion method (according to EUCAST criteria 2023/2024).
Several findings in the literature suggest a correlation between NDM-type β-lactamases and important increases in cefiderocol MIC, demonstrated by the introduction of NDM genes in isogenic mutants [35,36,37] and the much higher prevalence (42–59% in some cohorts) [38,39,40] of cefiderocol nonsusceptibility in blaNDM-producing isolates from clinical practices. Moreover, NDM expression appears to facilitate the emergence of cefiderocol resistance through additional mechanisms (such as mutations in siderophore receptors) [41].
An alarming resistance to cefiderocol is likely to develop over time owing to the increasing number of blaNDM strains, as seen in our epidemiological findings. Cross-resistance among ceftazidime–avibactam, ceftolozane–tazobactam, and cefiderocol has been reported and is associated with KPC variants in K. pneumoniae [24,41] or AmpC variants in Enterobacter spp. and P. aeruginosa [42].
In Romania, cefiderocol is approved by the National Agency of Medicine and Medical Devices but is hardly accessible. Other compounds such as colistin, fosfomycin, tigecycline, minocycline, and eravacycline could have significant toxicity, or these compounds may achieve poor concentrations in some infection sites. CR-KP is also developing resistance to these agents at an alarming rate [37].
The combination aztreonam–avibactam has been studied given that ATM is stable against metallo-β-lactamases and avibactam can protect against aztreonam-hydrolyzing enzymes, including ESBLs and AmpC β-lactamases, which are often coproduced by these highly resistant variants [43].
A study conducted on 422 patients with complicated intra-abdominal infections (CIAI) or HAP/VAP comparing aztreonam–avibactam versus meropenem–colistin showed the first combination was effective, displaying similar efficacy and good outcomes at 28-day all-cause mortality. A systematic review including 35 in vitro and 18 in vivo studies on the combination aztreonam–avibactam for MBL producers revealed clinical resolution within 30 days for 80% of infected patients [44,45].
Our study is limited by the small number of patients in the case series. In our region, resistance genes are not routinely tested for, and the first option for clinicians is treatment based on little epidemiological data and clinical and microbiological indicators. All these factors make medical decisions and treatment options difficult regarding CR-Kp co-producing blaOXA-48 and blaNDM, particularly when there is limited access to other active novel antibiotics.

4. Materials and Methods

4.1. Setting and Patients

In this observational, retrospective, noninterventional study, we reviewed the outcomes of 7 patients who were admitted to the Clinical Emergency Hospital “Agrippa Ionescu”, Bucharest, Romania, between October 2023 and January 2024. We selected all patients with CR-Kp producing blaNDM + blaOXA-48 isolated in cultures; with demonstrated resistance to C/A, monobactams, and carbapenems; and who were treated with the synergic combination of C/A + ATM. An infectious diseases physician was consulted in all cases, and all patients consented to the treatment. Both antibiotics are approved for use by the Romanian National Agency of Medicines and Medical Devices.
The specimens were acquired from different sites: urinary tract, bloodstream, and intra-abdominal collections. We included patients with bacteriaemia, symptomatic site infections, or asymptomatic site infections. Symptomatic site infections were described as positive cultures with organ-specific symptoms, signs of generalized infection, or inflammatory responses. Asymptomatic site infections were defined as positive cultures with inflammatory responses and without any clinical manifestations.
To evaluate inflammatory responses, we monitored C-reactive protein levels. Clinical recovery was defined as the remission of systemic or generalized clinical signs of infection (fever, shivers, dysuria, and abdominal pain) associated with a significant decrease in the inflammatory response (obtaining a C-reactive protein level below 10 mg/L) during the follow-up period. Microbiological recovery was achieved when negative cultures were obtained. Patients were followed up for 30 days after treatment. Recurrence was defined as a new positive culture with or without clinical signs and symptoms of infection after the first clinical or microbiological success.

4.2. Microbiology

A total of 7 specimens were obtained with the described characteristics. Bacterial identification and antibiotic susceptibility testing were performed with Vitek2 compact (BioMerieux, Mercy-l’Étoile, France), and the results were interpreted in accordance with the EUCAST 2023 criteria. The breakpoints used for defining resistance for meropenem and C/A were an MIC of >8 mg/L; for ATM, an MIC of >4 mg/L; and for colistin, an MIC of >2 mg/L. Cefiderocol sensitivity was tested in vitro via disk diffusion (R < 23 mm) as per the EUCAST 2023 criteria. A double-disk diffusion test was performed for all isolates to determine the effect of C/A and ATM in combination with each other against the resistant microorganism. Mueller–Hinton agar (BioMerieux, Mercy-l’Étoile, France) was inoculated with a saline suspension from a fresh culture of the isolated microorganism adjusted to 0.5 McFarland turbidity standard. The synergism was tested by placing 2 antibiotic disks of C/A (10/4 μg) CZA 14 and ATM 30 μg (Oxoid, Hampshire, UK) 20 mm from each other (center to center). After 16 to 20 h of incubation, a synergistic effect was present in the two antibiotics, and an inhibition zone formed between the disks. Molecular resistance mechanisms including KPC, VIM, OXA-48, NDM, IMP, and CTX-M were assessed through immunochromatographic direct detection with rapid NG-Test Carba-5 (NG Biotech, Guipry-Messac, France).

4.3. Analyzed Variables

The data were obtained from a microbiology laboratory database and the patients’ electronic records. In addition to demographics, other risk factors included the following: admission to a ward with a high risk of acquiring MDR infection or colonization; previous hospitalizations in the last 3 months; surgery in the last 6 months and the type of surgery; presence of indwelling devices or invasive maneuvers during hospitalization; type and number of underlying comorbidities; Charlson index; colonization with MDR pathogens at admission on the wards or ICU; and prior antibiotic and carbapenem exposure in the last 3 months (Figure 1, Figure 2, Figure 3, Figure 4 and Figure 5).
We analyzed the specimen collection site, susceptibility to antibiotics with MIC testing, beta-lactamase production testing, and Ambler class classification, as seen in Table 1.
We monitored the duration of treatment; the length of hospitalization; clinical and microbiological recovery; re-admission by day 30 after discharge owing to infection with CR-Kp or other non-related affections; and 30-day mortality by any cause (Table 2).

4.4. Treatment

All patients received combination therapy with 2.5 g C/A every 8 h and 2 g ATM every 8 h in prolonged infusion over 3 h according to the IDSA 2023 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections, except for 1 patient with prior end-stage kidney disease (included in a dialysis program). In this case, higher doses were preferred to creatinine-clearance-adjusted doses to ensure a higher serum concentration, as the antibiotic serum concentration measurement could not be performed at our hospital. None of the patients received any other antibiotics simultaneously.

5. Conclusions

In the current scenario, we aimed to highlight the fact that good knowledge of epidemiological data and molecular resistance mechanisms leads to appropriate therapeutic choices.
Our clinical data suggest that combination therapy with C/A plus ATM is a safe and efficient therapeutic option for treating severe infections caused by CR-Kp producing MBLs associated or not associated with OXA 48 and CTX-M, and this should be considered a first-line therapeutic option in the absence of other β-lactam or non-β-lactam antibiotics.
The optimal use of old or novel antibiotics or a synergistic combination of antibiotics represents an effective strategy against AMR development and improves prognosis.
Infection prevention and control are also critical for reducing the spread of microorganisms producing MBLs in healthcare systems.

Author Contributions

Conceptualization, I.M.C., M.C.V. and V.G.; methodology, I.M.C., M.C.V. and V.G.; software, I.M.C., M.C.V., E.S., T.H. and V.G.; validation, I.M.C., M.C.V. and V.G.; formal analysis, I.M.C., M.C.V., V.M. and V.G.; investigation, I.M.C., M.C.V. and V.G.; resources, T.H., E.S., I.M.C., M.C.V., V.M., A.M.R. and V.G.; data curation, I.M.C., M.C.V. and V.G.; writing—original draft preparation, I.M.C., M.C.V. and V.G.; writing—review and editing, I.M.C., M.C.V., E.S. and V.G.; visualization, I.M.C., M.C.V., A.M.R. and V.G.; supervision, I.M.C., M.C.V., A.M.R., E.S., V.M., A.M.R. and V.G.; project administration, I.M.C., M.C.V. and V.G.; funding acquisition, I.M.C., M.C.V. and V.G. All authors have read and agreed to the published version of the manuscript.

Funding

The publication of this paper was supported by the University of Medicine and Pharmacy Carol Davila through the institutional program Publish not Perish.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Prof. Dr. Agrippa Ionescu Clinical Emergency Hospital (protocol no. 241564/1 April 2024).

Informed Consent Statement

Written informed consent was obtained from all subjects and/or family members involved as part of the hospital admission procedure.

Data Availability Statement

The data are contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Martin, R.M.; Bachman, M.A. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front. Cell. Infect. Microbiol. 2018, 8, 4. [Google Scholar] [CrossRef] [PubMed]
  2. Tesfa, T.; Mitiku, H.; Edae, M.; Assefa, N. Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: Systematic review and meta-analysis. Syst. Rev. 2022, 11, 240. [Google Scholar] [CrossRef]
  3. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report for 2020. Available online: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2020 (accessed on 20 March 2024).
  4. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report for 2021. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2021 (accessed on 20 March 2024).
  5. Smith, R.M.; Lautenbach, E.; Omulo, S.; Araos, R.; Call, D.R.; Kumar, G.C.P.; Chowdhury, F.; McDonald, C.L.; Park, B.J. Human Colonization with Multidrug-Resistant Organisms: Getting to the Bottom of Antibiotic Resistance. Open Forum Infect. Dis. 2021, 8, ofab531. [Google Scholar] [CrossRef] [PubMed]
  6. Troeman, D.P.R.; Hazard, D.; Timbermont, L.; Malhotra-Kumar, S.; van Werkhoven, C.H.; Wolkewitz, M.; Ruzin, A.; Goossens, H.; Bonten, M.J.M.; Harbarth, S.; et al. Postoperative Staphylococcus aureus Infections in Patients with and Without Preoperative Colonization. JAMA Netw. Open 2023, 6, e2339793. [Google Scholar] [CrossRef] [PubMed]
  7. Radu, F.I.; Mates, I.M.; Gheorghita, V. Bucharest Mobile Military Hospital-Response to the COVID-19 Pandemic. 2020. Available online: https://www.revistamedicinamilitara.ro/wp-content/uploads/2020/04/Bucharest-mobile-military-hospital-%E2%80%93-response-to-the-COVID-19-pandemic.pdf (accessed on 22 May 2024).
  8. Gheorghiță, V.; Conea, I.F.; Radu, A.M.; Ștefan, I.; Mărdărescu, M.; Petrea, S.; Streinu-Cercel, A. Epidemiological trends and therapeutic challenges of malignancies in adult HIV-1-infected patients receiving combination antiretroviral therapy in a tertiary hospital from Romania: An observational retrospective study. J. Infect. Public Health 2019, 12, 182–189. [Google Scholar] [CrossRef] [PubMed]
  9. CARMIAAM-ROM 2021. Available online: https://insp.gov.ro/download/carmiaam-2021/e (accessed on 22 May 2024).
  10. Antibiotic Resistance: A Global Threat|CDC. Available online: https://www.cdc.gov/drugresistance/solutions-initiative/stories/ar-global-threat.html (accessed on 20 March 2024).
  11. Operational Public Health Considerations for the Prevention and Control of Infectious Diseases in the Context of Russia’s Aggression towards Ukraine. Available online: https://www.ecdc.europa.eu/en/publications-data/operational-public-health-considerations-prevention-and-control-infectious (accessed on 20 March 2024).
  12. Holt, K.E.; Wertheim, H.; Zadoks, R.N.; Baker, S.; Whitehouse, C.A.; Dance, D.; Jenney, A.; Connor, T.R.; Hsu, L.Y.; Severin, J.; et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc. Natl. Acad. Sci. USA 2015, 112, E3574–E3581. [Google Scholar] [CrossRef] [PubMed]
  13. David, S.; Reuter, S.; Harris, S.R.; Glasner, C.; Feltwell, T.; Argimon, S.; Abudahab, K.; Goater, R.; Giani, T.; Errico, G.; et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat. Microbiol. 2019, 4, 1919–1929. [Google Scholar] [CrossRef] [PubMed]
  14. Docquier, J.-D.; Mangani, S. An update on β-lactamase inhibitor discovery and development. Drug Resist. Updat. 2018, 36, 13–29. [Google Scholar] [CrossRef]
  15. Temkin, E.; Torre-Cisneros, J.; Beovic, B.; Benito, N.; Giannella, M.; Gilarranz, R.; Jeremiah, C.; Loeches, B.; Machuca, I.; Jiménez-Martín, M.J.; et al. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Antimicrob. Agents Chemother. 2017, 61. [Google Scholar] [CrossRef]
  16. Shlaes, D.M. New β-lactam–β-lactamase inhibitor combinations in clinical development. Ann. N. Y. Acad. Sci. 2013, 1277, 105–114. [Google Scholar] [CrossRef]
  17. Sandfort, M.; Hans, J.B.; Fischer, M.A.; Reichert, F.; Cremanns, M.; Eisfeld, J.; Pfeifer, Y.; Heck, A.; Eckmanns, T.; Werner, G.; et al. Increase in NDM-1 and NDM-1/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022. Eurosurveillance 2022, 27, 2200926. [Google Scholar] [CrossRef] [PubMed]
  18. Boyd, S.E.; Holmes, A.; Peck, R.; Livermore, D.M.; Hope, W. OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline. Antimicrob. Agents Chemother. 2022, 66, e0021622. [Google Scholar] [CrossRef] [PubMed]
  19. Glasner, C.; Albiger, B.; Buist, G.; Andrašević, A.T.; Cantón, R.; Carmeli, Y.; Friedrich, A.W.; Giske, C.G.; Glupczynski, Y.; Gniadkowski, M.; et al. Carbapenemase-producing Enterobacteriaceae in Europe: A survey among national experts from 39 countries, February 2013. Eurosurveillance 2013, 18, 20525. [Google Scholar] [CrossRef]
  20. Liu, Y.; Long, D.; Xiang, T.-X.; Du, F.-L.; Wei, D.D.; Wan, L.-G.; Deng, Q.; Cao, X.-W.; Zhang, W. Whole genome assembly and functional portrait of hypervirulent extensively drug-resistant NDM-1 and KPC-2 co-producing Klebsiella pneumoniae of capsular serotype K2 and ST86. J. Antimicrob. Chemother. 2019, 74, 1233–1240. [Google Scholar] [CrossRef]
  21. Wei, D.-D.; Wan, L.-G.; Liu, Y. Draft Genome Sequence of an NDM-1- and KPC-2-Coproducing Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae Strain Isolated from Burn Wound Infections. Genome Announc. 2018, 6, e00192-18. [Google Scholar] [CrossRef]
  22. Bes, T.; Nagano, D.; Martins, R.; Marchi, A.P.; Perdigão-Neto, L.; Higashino, H.; Prado, G.; Guimaraes, T.; Levin, A.S.; Costa, S. Bloodstream Infections caused by Klebsiella pneumoniae and Serratia marcescens isolates co-harboring NDM-1 and KPC-2. Ann. Clin. Microbiol. Antimicrob. 2021, 20, 57. [Google Scholar] [CrossRef] [PubMed]
  23. Kumarasamy, K.; Kalyanasundaram, A. Emergence of Klebsiella pneumoniae isolate co-producing NDM-1 with KPC-2 from India. J. Antimicrob. Chemother. 2012, 67, 243–244. [Google Scholar] [CrossRef]
  24. Bianco, G.; Boattini, M.; Comini, S.; Casale, R.; Iannaccone, M.; Cavallo, R.; Costa, C. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 573–580. [Google Scholar] [CrossRef]
  25. Guo, H.; Wu, Y.; Li, L.; Wang, J.; Xu, J.; He, F. Global emergence of carbapenem-resistant Klebsiella pneumoniae co-carrying multiple carbapenemases. Comput. Struct. Biotechnol. J. 2023, 21, 3557–3563. [Google Scholar] [CrossRef]
  26. Székely, E.; Damjanova, I.; Jánvári, L.; Vas, K.E.; Molnár, S.; Bilca, D.V.; Lőrinczi, L.K.; Tóth, A. First description of bla(NDM-1), bla(OXA-48), bla(OXA-181) producing Enterobacteriaceae strains in Romania. Int. J. Med. Microbiol. 2013, 303, 697–700. [Google Scholar] [CrossRef] [PubMed]
  27. Dortet, L.; Flonta, M.; Boudehen, Y.-M.; Creton, E.; Bernabeu, S.; Vogel, A.; Naas, T. Dissemination of Carbapenemase-Producing Enterobacteriaceae and Pseudomonas aeruginosa in Romania. Antimicrob. Agents Chemother. 2015, 59, 7100–7103. [Google Scholar] [CrossRef] [PubMed]
  28. Gheorghe, I.; Czobor, I.; Chifiriuc, M.C.; Borcan, E.; Ghiţă, C.; Banu, O.; Lazăr, V.; Mihăescu, G.; Mihăilescu, D.F.; Zhiyong, Z. Molecular screening of carbapenemase-producing Gram-negative strains in Romanian intensive care units during a one year survey. J. Med. Microbiol. 2014, 63 Pt 10, 1303–1310. [Google Scholar] [CrossRef]
  29. Molnar, S.; Vas, K.E.; Szekely, E. Carbapenemase Producing Enterobacterales in Romania: Investigating the Origins. Rom. Rev. Lab. Med. 2020, 28, 341–348. [Google Scholar] [CrossRef]
  30. Lixandru, B.E.; Cotar, A.I.; Straut, M.; Usein, C.R.; Cristea, D.; Ciontea, S.; Tatu-Chitoiu, D.; Codita, I.; Rafila, A.; Nica, M.; et al. Carbapenemase-Producing Klebsiella pneumoniae in Romania: A Six-Month Survey. PLoS ONE 2015, 10, e0143214. [Google Scholar] [CrossRef] [PubMed]
  31. Tamma, P.D.; Aitken, S.L.; Bonomo, R.A.; Mathers, A.J.; van Duin, D.; Clancy, C.J. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin. Infect. Dis. 2022, 74, 2089–2114. [Google Scholar] [CrossRef] [PubMed]
  32. Shaw, E.; Rombauts, A.; Tubau, F.; Padullés, A.; Càmara, J.; Lozano, T.; Cobo-Sacristán, S.; Sabe, N.; Grau, I.; Rigo-Bonnin, R.; et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J. Antimicrob. Chemother. 2018, 73, 1104–1106. [Google Scholar] [CrossRef] [PubMed]
  33. Marshall, S.; Hujer, A.M.; Rojas, L.J.; Papp-Wallace, K.M.; Humphries, R.M.; Spellberg, B.; Hujer, K.M.; Marshall, E.K.; Rudin, S.D.; Perez, F.; et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob. Agents Chemother. 2017, 61. [Google Scholar] [CrossRef]
  34. Davido, B.; Fellous, L.; Lawrence, C.; Maxime, V.; Rottman, M.; Dinh, A. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy to Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2017, 61. [Google Scholar] [CrossRef]
  35. Kohira, N.; Hackel, M.A.; Ishioka, Y.; Kuroiwa, M.; Sahm, D.F.; Sato, T.; Maki, H.; Yamano, Y. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J. Glob. Antimicrob. Resist. 2020, 22, 738–741. [Google Scholar] [CrossRef]
  36. Poirel, L.; Sadek, M.; Nordmann, P. Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2021, 65, AAC0087721. [Google Scholar] [CrossRef]
  37. Lan, P.; Lu, Y.; Chen, Z.; Wu, X.; Hua, X.; Jiang, Y.; Zhou, J.; Yu, Y. Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China. Microbiol. Spectr. 2022, 10, e0008422. [Google Scholar] [CrossRef] [PubMed]
  38. Karlowsky, J.A.; Kazmierczak, K.M.; de Jonge, B.L.M.; Hackel, M.A.; Sahm, D.F.; Bradford, P.A. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob. Agents Chemother. 2017, 61. [Google Scholar] [CrossRef] [PubMed]
  39. Mushtaq, S.; Sadouki, Z.; Vickers, A.; Livermore, D.M.; Woodford, N. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. Antimicrob. Agents Chemother. 2020, 64. [Google Scholar] [CrossRef] [PubMed]
  40. Longshaw, C.; Manissero, D.; Tsuji, M.; Echols, R.; Yamano, Y. In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC-Antimicrob. Resist. 2020, 2, dlaa060. [Google Scholar] [CrossRef] [PubMed]
  41. Nurjadi, D.; Kocer, K.; Chanthalangsy, Q.; Klein, S.; Heeg, K.; Boutin, S. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae. Antimicrob. Agents Chemother. 2022, 66, e0201121. [Google Scholar] [CrossRef]
  42. Poirel, L.; Sadek, M.; Kusaksizoglu, A.; Nordmann, P. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 677–680. [Google Scholar] [CrossRef]
  43. Tompkins, K.; van Duin, D. Treatment for carbapenem-resistant Enterobacterales infections: Recent advances and future directions. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 2053–2068. [Google Scholar] [CrossRef]
  44. Carmeli, Y.; Cisneros, J.-M.; Paul, M.; Daikos, G.L.; Wang, M.; Cisneros, J.T.; Singer, G.; Titov, I.; Gumenchuk, I.; Zhao, Y.; et al. 2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study. Open Forum Infect. Dis. 2023, 10 (Suppl. S2), ofad500.2476. [Google Scholar] [CrossRef]
  45. Mauri, C.; Maraolo, A.E.; Di Bella, S.; Luzzaro, F.; Principe, L. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics 2021, 10, 1012. [Google Scholar] [CrossRef]
Antibiotics 13 00550 g001
Figure 1. Patient medical history.
Figure 1. Patient medical history.
Antibiotics 13 00550 g001
Antibiotics 13 00550 g002
Figure 2. Underlying diseases.
Figure 2. Underlying diseases.
Antibiotics 13 00550 g002
Antibiotics 13 00550 g003
Figure 3. Associated comorbidities.
Figure 3. Associated comorbidities.
Antibiotics 13 00550 g003
Antibiotics 13 00550 g004
Figure 4. Type of invasive procedures.
Figure 4. Type of invasive procedures.
Antibiotics 13 00550 g004
Antibiotics 13 00550 g005
Figure 5. Previous bacterial colonization and type of bacteria.
Figure 5. Previous bacterial colonization and type of bacteria.
Antibiotics 13 00550 g005
Table 1. Bacterial characteristics; source of infection; type of carbapenemase; susceptibility profile.
Table 1. Bacterial characteristics; source of infection; type of carbapenemase; susceptibility profile.
PatientPrevious Antibiotic/Carbapenem ExposureSiteAmbler Classβ-LactamasesC/A (MIC)ATM (MIC)SYN CefiderocolColistin (MIC)Meropenem (MIC)TigecyclineFosfomycin
1No/NoUrinaryA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesSR (>16 mg/L)R (>16 mg/L)SR
2Yes/NoUrinaryA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesSS (0.5 mg/L)R (>16 mg/L)RR
3Yes/YesBacteriemiaA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesSR (>16 mg/L)R (>16 mg/L)I-
4Yes/YesBiliaryA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesSR (>16 mg/L)R (>16 mg/L)R-
5Yes/NoUrinaryA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesRR (>16 mg/L)R (>16 mg/L)RR
6Yes/NoUrinaryA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesSR (>16 mg/L)R (>16 mg/L)IR
7Yes/YesPeritonealA, B + DNDM + Oxa-48 + CTX-MR (>16 mg/L)R (>64 mg/L)YesSR (>16 mg/L)R (>16 mg/L)RR
C/A—ceftazidime–avibactam; ATM—aztreonam; SYN—synergism between ceftazidime–avibactam and aztreonam; R—resistant; S—sensitive; I—intermediate.
Table 2. Characteristics and outcomes of patients treated with ceftazidime–avibactam and aztreonam.
Table 2. Characteristics and outcomes of patients treated with ceftazidime–avibactam and aztreonam.
PatientDuration of TreatmentDoses (C/A + ATM)Length of Hospitalization (Days)Clinical RecoveryMicrobiological RecoveryRecurrence at 30 DaysRe-Admission (Other) at 30 DaysDeath at 30 Days
172.5 g q8h + 2 g q8h12YesYesNoYesNo
272.5 g q8h + 2 g q8h10YesYesNoYesNo
3102.5 g q8h + 2 g q8h>30YesYesNoYesNo
472.5 g q8h + 2 g q8h28YesN/ANoNoNo
5142.5 g q8h + 2 g q8h14YesYesNoYesNo
6121.25 q12h + 2 g q12h20YesYesNoNoNo
772.5 g q8h + 2 g q8h>30YesNoNoNoNo
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cismaru, I.M.; Văcăroiu, M.C.; Soium, E.; Holban, T.; Radu, A.M.; Melinte, V.; Gheorghiță, V. Synergistic Combination of Aztreonam and Ceftazidime–Avibactam—A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania. Antibiotics 2024, 13, 550. https://doi.org/10.3390/antibiotics13060550

AMA Style

Cismaru IM, Văcăroiu MC, Soium E, Holban T, Radu AM, Melinte V, Gheorghiță V. Synergistic Combination of Aztreonam and Ceftazidime–Avibactam—A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania. Antibiotics. 2024; 13(6):550. https://doi.org/10.3390/antibiotics13060550

Chicago/Turabian Style

Cismaru, Ioana Miriana, Maria Cristina Văcăroiu, Elif Soium, Tiberiu Holban, Adelina Maria Radu, Violeta Melinte, and Valeriu Gheorghiță. 2024. "Synergistic Combination of Aztreonam and Ceftazidime–Avibactam—A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania" Antibiotics 13, no. 6: 550. https://doi.org/10.3390/antibiotics13060550

APA Style

Cismaru, I. M., Văcăroiu, M. C., Soium, E., Holban, T., Radu, A. M., Melinte, V., & Gheorghiță, V. (2024). Synergistic Combination of Aztreonam and Ceftazidime–Avibactam—A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania. Antibiotics, 13(6), 550. https://doi.org/10.3390/antibiotics13060550

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop